Summit Therapeutics Inc. Financials

Market Capitalization $18.18 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	25.02
Forward PE	-64.87
Price to Sales TTM	$
Price to Book MRQ	$41.50
Enterprise to Revenue
Enterprise to EBITDA	-97.66

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	0.00%
Return on Assets TTM	-31.47%
Return on Equity TTM	-73.21%

Income Statement

Revenue TTM	$0
Revenue per Share TTM	$0.00
Quarterly Revenue Growth	%
Gross Profit TTM	$0
EBITDA	$-181,490,000
Net Income to Common TTM	$-196,679,008
Diluted EPS TTM	$-0.23
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$486,896,992
Total Cash per Share MRQ	$0.66
Total Debt MRQ	$
Total Debt to Equity MRQ	7.42
Current Ratio MRQ	8.31
Book Value per Share MRQ	$0.59

Cash Flow

Operating Cash Flow TTM	$-112,892,000
Levered Free Cash Flow TTM	$-62,823,624

SMMT Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	737,448,000
Float Shares	105,056,863
Avg 10 Volume	3,049,450
Avg 30 Volume	None
Shares Short	19,939,807
Short Ratio	9.05
Short % of Shares	16.78%
% Held by Insiders	84.36%
% Held by Institutions	11.74%

Stock Price Summary

Beta	-0.92
Fifty Two Week Low	$2.10
Fifty Two Week High	$33.89
Fifty Two Week Change	84.13%
Day 50 MA	$18.88
Day 200 MA	$13.63

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date